Trial of Inhaled Molgramostim in Cystic Fibrosis Subjects With Nontuberculous Mycobacterial Infection
Status:
Terminated
Trial end date:
2020-10-02
Target enrollment:
Participant gender:
Summary
A study to evaluate the efficacy of inhaled molgramostim administered open-label to adult
cystic fibrosis (CF) subjects with chronic pulmonary nontuberculous mycobacterial (NTM)
infection, with or without ongoing antimycobacterial guideline based combination therapy.